Journal de biologie des cytokines

Abstrait

Therapeutic Monoclonal Antibodies Targeting Cytokine Storm: Inclusion as a Future Treatment for the Severe Cases of COVID-19

Shikha Patel, Bhagawati Saxena, Priti Mehta

Clinical studies have manifested immunotherapeutics as the most propitious for the management of COVID-19 so far. However, the springing up variants of SARS CoV-2 has positioned the role of preventive immunotherapeutics – vaccines in doubt. Even so therapeutic monoclonal antibodies, Tocilizumab – an IL-6 inhibitor and Ravulizumab – a complement protein C5a blocker which are in clinical trial phase –IV are ascertained to be effectual for the COVID-19 cytokine storm and are envisioned to be included as an approved treatment for the severe COVID-19 cases.